In addition, lncRNA MEG3 has a profound research foundation in tumor diseases, first showing biomarker value in straight-colon cancer (Wang et al., 2019c), gastric cancer (Ghaedi et al., 2019), breast cancer (Ali et al., 2020) and other cancers (Duan et al., 2016; Zhao et al., 2018; Ali et al., 2020). Here, MEG3 is linked to breast cancer.